References
1. Shibiru T, Gudina EK, Habte B, Derbew A, Agonafer T. Survival pattern of patients on maintenance hemodialysis for end stage renal disease in Ethiopia: summary of 91 cases. BMC Nephrol. 2015; 14(127):1-6.
2. Dash SC, Agarwal SK. Incidence of chronic kidney disease in India. Nephrol Dial Transplantation 2006; 21:232-233.
3. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function : A meta analysis. Am J Kidney Dis. 2002; 40(2): 221-226.
4. Roos JF, Doust J, Tett SE, Kirkpatrick CM. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children – A meta analysis. Clin Biochem. 2007; 40(5-6): 383-391.
5. Gheissari A, Roomizadeh P, Abedini A. A more accurate replacement for the revised Schwartz equation:quadratic or Flanders metadata?. Kidney International. 2013; 84(2): 416–417.
6. Shilpasree AS, Prakash S, Itagappa M. Cystatin C : A better indicator than creatinine to assess the renal functions. Int J of Phar and Biol Sci. 2013; 3:372-377.
7. Vanholder R.Uremic toxins. Nephrol. 1997; 26: 143-163.
8. Vanholder R, De Smet R, Glorieux G, Argiles A, Baurmeister U, Brunet P, Clark W, Cohen G, De Deyn PP, Deppisch R, Descamps-Latscha B, Henle T, Jorres A, Lemke HD, Massy ZA, Passlick-Deetjen J, Rodriguez M, Stegmayr B, Stenvinkel P, Tetta C, Wanner C, Zidek W: Review on uremic toxins: Classification, concentr-ation, and interindividual variability Kidney Int 63: 1934-1943 (2003)
9. Filler G, Bokenkamp A, Hoffman W, Bricon, TL, Martinez-Bru, C, Grubb A. Cystatin C a marker of GFR- history, indications and future research. Clin Biochem. 2004; 38(1): 1-8.
10. Fossum K, Whitaker JR. Ficin and papain inhibitor from chicken egg white. Arch Biochem Biophys. 1968; 125:367–375.
11. Fossum K, Whitaker JR. Ficin and papain inhibitor from chicken egg white. Arch Biochem Biophys. 1968; 125:367–375.
12. Butler EA, Flynn FV. The occurrence of post-gamma protein in urine: a new protein abnormality. J Clin Pathol 1961;14:172–8.
13. Sophie SV,Pierre D, Laurence P,Christophe M,Marc F, Jean PC. Cystatin C : current position and future prospects. Clin Chem Lab Med 2008; 46(12): 1664-86.
14. Cejka J,Fleishman LE (1973).Postglobulin isolation and physiochemical characteriza-tion. Arch Biochem Biophys 157:168-176
15. Colle A, Guinet R, Leclercq M, Manuel Y. Occurrence of beta2-microglobulin and post-gamma globulin in human semen. Clin Chim Acta 1976;67:93–7
16. Hochwald GM, Thorbecke GJ. Trace proteins in cerebrospinal fluid and other biological fluids. I. Effect of various fractionation procedures on beta-trace and gamma-trace proteins and methods for isolation of both proteins. Arch Biochem Biophys 1963;101:325–34.
17. Sambasivan AS, Lepage N, Filler G. Cystatin C intrapatient variability in children with chronic kidney disease is less than serum creatinine. Clin chem. 2005; 51(11):2215-2216.
18. Finney H, Newman DJ, Price CP. Adult reference ranges for serum cystatin c, creatinine and predicted creatinine cleara-nce. Ann clin biochem. 2000; 37( 1): 49-50.
19. Chhetri PK, Manandhar DN, Bhattarai SP, Pahari LR, Shrestha R. Chronic Kidney disease 5 on hemodialysis in Nepal Medical College Teaching hospital. Nepal Medical College. Journal NMCJ. 2008; 10(1):8-10
20. Hoek FJ, Korevaar JC, Dekker FW, Boeschoten EW, Krediet RT. Estimation of residual glomerular filtration rate in dialysis patients from the plasma cystatin C level. Nephrol Dial Transplant. 2007; 22(6): 861-875.
21. Coggins CH,Breyer LJ,Caqquila AW,Castaldo LS,Klahr S,Wang SR. Differences between women and men with chronic renal disease. Nephrol Dial Transplant. 1998;13(6):1430-7.
22. Raveira M, Re, M, Deferrari, L, Vettoretti, S, Deferrari,G. Importance of Blood pressure control in chronic kidney disease. J Am Soc Nephrol. 2006; 17(40: S98-S103.
23. Luke RG. Hypertensive nephrosclerosis: pathogenesis and prevalence. Essential hypertension is an important cause of end stage renal disease. Nephrology Dialysis transplantation. 1999;14(10):437-439 2271-8.
24. Ramprasad N, Al-Gohnaim MI. Role of trace elements and lipid peroxidation levels in pre and post hemodialysis of chronic renal failure patient. Int J research biochem and biophysics. 2013; 3(1):1-6.
25. Agraharkar M, Nair V, Patlovany M. Recovery of renal function in dialysis patients. BMC Nephrol. 2013; 4( 9): 1-5.
26. Heymsfield SB, Stevens V, Noel R, ct al. Biochemi- cal composition of muscle in normal and proteinenergy starved human subjects: relevance to anthropometric measurements. Am J Clin Nutr 1982;36: 131-42.
27. Proctor DN, O’Brien PC, Atkinson EJ, Nair KS (1999) Comparison of techniques to estimate total body skeletal muscle mass in people of different age groups. Am J Physiol 277: E489–495.
28. Krishnamurthy N, Arumugasamy K, Anand U, Anand CV, Aruna V, Venu G, et al. Effect of dialysis in circulating cystatin C levels in patients with end stage renal disease. Ind J of Clin Biochem. 2010; 25(1): 43-46.
29. Lindstrom V, Grubb A, Alquist HM, Christensson A. Different elimination patterns of beta trace protein, beta2 microglobulin and cystatin C in hemodial-ysis, hemodiafiltration and hemofiltration. Scan J clin Invest. 2008; 68(8): 685-691.
30. Al-Malki N, Heidenheim PA, Filler G, Yasin A, Lindsay RM. Cystatin c levels in functionally anephric patients undergoing dialysis: the effect of different methods and intensities. Clin J Am Soc Nephrol. 2009; 4(10):1606-1610.
31. Huang SH, Filler G, Yasin A, Lindsay RM. Cystatin C reduction ratio depends on normalized blood liters processed and fluid removal during hemodialysis. Clin J Am Soc Nephrol. 2011;6:319–25.
32. Kabanda A,Jadoul M,Pochet JM et.al. Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int.1994:45;1689-96
33. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: A cross sectional and longitudinal study. J gerontol. 1976; 31(2):155-163.
34. Banfi G, Sloand J, Shelly M, Fabro MD, Barassi A, D’Eril GVM. Limitations of cockroft Gault and MDRD formulas in estimating GFR among top level rugby players.J Nephrol. 2012; 25(6):1047-1053.
35. Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thysell, H. Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand. 1985; 218(5): 499-503.
36. Erlandsen E J, Randers E, Krishten sen JH (1998). Reference intervals for serum cystatin C and serum creatinine in adults. Clin. Chem. lab Med ; 36; 393 – 7.
37. Kumaresan R, Giri P. A comparison of serum cystatin C and creatinine with glomerular filtration rate in Indian patients with chronic kidney disease. Oman Med J.2011; 26(6):421-425.
38. Knight EL,Verhave JC,Spiegelman D, Hillege HL,Zeeuw DD,Curhan GC,Dejong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney International,vol 65(2004); 1416-1421.
39. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007; 115: 173–179.